RecruitingPhase 3NCT07517263
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Studying Isolated pulmonary artery sling
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- Pelacarsen (TQJ230)(drug)
- Enrollment
- 5700 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2026 – 2030
Study locations (30)
- SEC Clinical Research LLC, Andalusia, Alabama, United States
- Heart Center Research Llc, Huntsville, Alabama, United States
- Mobile Heart Specialists, Mobile, Alabama, United States
- Mercy Gilbert Medical Center, Gilbert, Arizona, United States
- Clinical Research Inst of Arizona, Sun City West, Arizona, United States
- Eclipse Clinical Research, Tucson, Arizona, United States
- Cardiovascular Res Found, Beverly Hills, California, United States
- National Heart Institute, Beverly Hills, California, United States
- UCSF, San Francisco, California, United States
- Helping Hands Medical Associates INC, Santa Ana, California, United States
- Manshadi Heart Institute, Stockton, California, United States
- Interv Cardiology Med Grp, West Hills, California, United States
- Chase Medical Research LLC, Waterbury, Connecticut, United States
- Bay Area Cardiology Assoc, Brandon, Florida, United States
- Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07517263 on ClinicalTrials.govOther trials for Isolated pulmonary artery sling
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07513571A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy AdultsAstraZeneca
- RECRUITINGNCT07508007Impact of Implementation Strategies on Lp(a) Testing in Secondary Care SettingsNovartis Pharmaceuticals
- ACTIVE NOT RECRUITINGNCT07533656VAP-Measured Lipid Subfractions and In-Stent Restenosis After PCISecond Affiliated Hospital, School of Medicine, Zhejiang University